Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study.

Basit Öğe Kaydı
dc.authorid0000-0001-6417-0840
dc.authorid0000-0002-7071-2471
dc.contributor.authorGümüş, Mahmut
dc.contributor.authorChen, Chieh-I
dc.contributor.authorIvanescu, Cristina
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorBondarenko, Igor
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorGogishvili, Miranda
dc.date.accessioned2025-05-10T19:34:29Z
dc.date.issued2021
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 04-08, 2021 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Soc Clin Oncol
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc; Sanofi
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc, and Sanofi
dc.identifier.doi10.1200/JCO.2021.39.15_suppl.9078
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1200/JCO.2021.39.15_suppl.9078
dc.identifier.urihttps://hdl.handle.net/20.500.14730/8544
dc.identifier.volume39
dc.identifier.wosWOS:000708120605058
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titlePatient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study.
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu